Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
90-232 |
DRI_Approach |
denotes |
Mutations in Leucine-rich repeat kinase 2 (LRRK2) gene are the most common cause of sporadic and familial late onset Parkinson's disease (PD). |
T2 |
233-334 |
DRI_Background |
denotes |
The G2019S common mutation has been identified about 1% of sporadic cases and 4-7% of familial cases. |
T3 |
335-444 |
DRI_Background |
denotes |
Over 50 variants have since been identified in LRRK2, and at least 7 of these are confirmed to be pathogenic. |
T4 |
445-633 |
DRI_Background |
denotes |
In addition to pathogenic mutations, several common polymorphisms in the LRRK2 gene (G2385R and R1628P) have been identified that may explain up to 10% of sporadic PD in Asian populations. |
T5 |
634-737 |
DRI_Background |
denotes |
LRRK2 is a large complex multidomain protein with 2,527-amino-acid and the molecular weight is 286 kDa. |
T6 |
738-743 |
REPLACED |
denotes |
LRRK2 |
T7 |
756-876 |
DRI_Background |
denotes |
protein consists of a catalytic core domain, kinase domain and a number of putative protein-protein interaction domains. |
T8 |
877-1052 |
DRI_Outcome |
denotes |
LRRK2 mutations found in PD families, including the G2019S and I2020T mutations show increased intrinsic kinase activity, when assessed with myelin basic protein as substrate. |
T9 |
1053-1286 |
DRI_Challenge |
denotes |
The modification of LRRK2 GTPase and kinase activity affecting residues in the ROC, COR and mitogen-activated protein kinase kinase kinases domains is believed to lead to neuronal cell death, but the pathways involved remain unclear. |
T10 |
1287-1425 |
DRI_Background |
denotes |
A number of in vivo models in C. elegans, D. melanogaster and mice have been developed to study the patho/physiological function of LRRK2. |
T11 |
1426-1668 |
DRI_Background |
denotes |
Based on current literature, a toxic gain of function in LRRK2 kinase activity is a possible pathophysiologic mechanism and thus inhibition of kinase activity in experimental models offers a potential therapeutic strategy for LRRK2-linked PD. |